Difference between the different tablet colors of Xanax

The differences between the different colors of the Xanax tablets are in the dose of alprazolam and in the type of tablet (immediate or prolonged release).

  • Xanax 0.25 mg immediate-release tablets are white. 
  • Xanax 0.5 mg immediate-release tablets are orange.
  • Xanax XR extended-release tablets of 1 mg are yellow,
  •  Xanax XR extended-release tablets of 2 mg are blue, 
  • Xanax XR prolonged-release tablets of 3 mg are green,
  • and Xanax XR 0.5 mg prolonged-release tablets are also white but are designed in 5-sided form.

What are Xanax bars? 

The Xanax bar is actually a 2 mg Xanax tablet that has the shape of a stick or stick, so it can be easily divided into 1/4 of 0.5 mg. This formulation allows an exact and optimum distribution of 0.5 mg of alprazolam in each bar room.

How does Xanax work?

Alprazolam is a benzodiazepine drug that works not specifically binding to benzodiazepine receptors BNZ1, which are responsible for nighttime sleep, and BNZ2, which are responsible for muscle relaxation, motor coordination, anticonvulsant activity and memory. Alprazolam can also be coupled to the GABAa-gamma-aminobutyric A receptors, so this interaction potentiates the effects of GABA on the brain, which is a strong inhibitory neurotransmitter, by increasing the affinity of GABA for the GABA receptor. When GABA binds to its receptors, it opens the chloride channels, resulting in hyperpolarization of the membrane that prevents further cellular excitation.

Unlike clorazepate, chlordiazepoxide and prazepam, alprazolam has a much shorter half-life and its metabolites have minimal activity. Like triazolam, alprazolam can have important pharmacological interactions involving the hepatic isoenzyme of cytochrome P-450 3A4. Like all benzodiazepines, alprazolam can also cause dose-related CNS depression that ranges from a mild deterioration of task performance to hypnosis. Another difference from other benzodiazepines is that alprazolam may also have some antidepressant activity; however, there is no important clinical evidence for this.

Who should not take Xanax?

  • Patients with depression  In those with preexisting depression, Xanax can worsen their condition due to their depressant effects in the CNS. If depression worsens or patients have suicidal thoughts, the doctor should be called immediately. Episodes of hypomania and mania have also been reported in depressed patients treated with Xanax.
  • Patients with acute narrow-angle glaucoma and untreated open-angle glaucoma. Xanax can make this condition worse. Do not take Xanax if you have acute narrow-angle glaucoma. Xanax has anticholinergic effects; however, it has been associated very rarely with an increase in intraocular pressure.
  • People with a history of alcoholism, drug abuse or personality disorder. Xanax can lead to psychological physics and addiction. Patients with a history of these conditions may have an increased risk of addiction to this medication.
  • Patients with kidney or liver disease. Xanax is metabolized in the liver and the metabolites are excreted in the urine. For patients with lower renal or hepatic function, it may be more difficult to metabolize and eliminate this medication from the body. This can increase the amount of Xanax in the blood and may increase the risk of causing serious side effects.
  • Patients with severe lung disease. Like all benzodiazepines, Xanax can also cause respiratory depression and apnea, usually when given in high doses. However, some patients may be more sensitive to recommended doses, such as elderly, debilitated or severely ill patients, patients with other central nervous system depressants, and those with limited ventilatory function, chronic lung failure or other respiratory disorders. Xanax therapy should be administered with caution and closely monitored in these patients.
  • Patients with Xanax epilepsy  may increase the incidence or precipitate the onset of generalized tonic-clonic seizures in patients with epilepsy. In addition, the abrupt cessation of Xanax may precipitate seizure attacks as withdrawal symptoms, usually after prolonged use of CNS depressants. Status epilepticus can also occur if long-term Xanax therapy is rapidly withdrawn.
  • Obese patients  The plasma half-lives of Xanax can be prolonged in obese patients, probably due to a greater distribution in fat. The amount of medication can increase in your body, which can increase the risk of side effects. Xanax should be administered with caution in obese patients, with careful control of the state of the CNS.
  • Patients allergic to Xanax or other benzodiazepines. Xanax can cause a severe allergic reaction in hypersensitive patients. Symptoms may include: difficulty breathing and swelling of the throat or tongue
  • Pregnant women. This medicine is classified in the FDA pregnancy category D drug list. That means: studies in humans have shown adverse effects for the fetus when the mother takes the medication. This medicine should only be used during pregnancy in severe cases where a dangerous condition needs to be treated in the mother. Patients should talk to their doctor if they are pregnant or plan to become pregnant. The doctor should inform you about the specific damage that can be done to the fetus when using this medicine. This medication should only be used if the potential risk to the fetus is acceptable given the potential benefits of the medication.
  • Mothers who are breastfeeding. Alprazolam can pass into breast milk and cause side effects in the baby. The baby may feel drowsy and lose weight. Mothers who are breastfeeding should talk to their doctor, and they may need to decide if they stop taking this medication or stop breastfeeding.
  • The elderly who are over 65 may become more sensitive to the sedative side effects of Xanax. They will be more sleepy. Physicians should monitor these patients closely. In addition, they must take special care to avoid falls that can be caused by drowsiness or dizziness.
  • Xanax should never be given to a child under 18 years of age.